MacroGenics Strikes Second Oncology Partnership With Servier
This article was originally published in The Pink Sheet Daily
Executive Summary
The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.